OMGA - Omega Therapeutics, Inc. Stock Price, Fair Value and News

$0.84+0.03 (+3.70%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

OMGA Price Action

Last 7 days

-13.4%

Last 30 days

6.3%

Last 90 days

-38.7%

Trailing 12 Months

-65%

OMGA RSI Chart

OMGA Valuation

Market Cap

46.5M

Price/Earnings (Trailing)

-0.64

Price/Sales (Trailing)

5.75

Price/Free Cashflow

-0.81

OMGA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

OMGA Fundamentals

OMGA Revenue

Revenue (TTM)

8.1M

Rev. Growth (Yr)

214.32%

Rev. Growth (Qtr)

22.4%

OMGA Earnings

Earnings (TTM)

-73.1M

Earnings Growth (Yr)

26.09%

Earnings Growth (Qtr)

-0.85%

OMGA Profitability

Return on Equity

-633.21%

Return on Assets

-47.86%

Free Cashflow Yield

-123.95%

OMGA Investor Care

Shares Dilution (1Y)

0.41%

Diluted EPS (TTM)

-1.32

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.9M	6.3M	8.1M	0
2023	2.3M	2.6M	2.8M	3.1M
2022	626.4K	1.1M	1.6M	2.1M
2021	0	0	0	144.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Omega Therapeutics, Inc.

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Mahesh Karande
WEBSITE	https://omegatherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	116

Omega Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Omega Therapeutics, Inc.? What does OMGA stand for in stocks?

OMGA is the stock ticker symbol of Omega Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Omega Therapeutics, Inc. (OMGA)?

As of Fri Dec 20 2024, market cap of Omega Therapeutics, Inc. is 46.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OMGA stock?

You can check OMGA's fair value in chart for subscribers.

Is Omega Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether OMGA is over valued or under valued. Whether Omega Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Omega Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OMGA.

What is Omega Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, OMGA's PE ratio (Price to Earnings) is -0.64 and Price to Sales (PS) ratio is 5.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OMGA PE ratio will change depending on the future growth rate expectations of investors.